CardiologyNOW | Begin CME/CE | Pri-Med

Thank you to all who joined us live for CardiologyNOW: A Pri-Med Virtual Conference on Thursday, June 17, 2021. If you were not able to join us, most sessions have been recorded and are available below.

Upcoming Virtual Conferences
Pri-Med has more virtual education planned. View our upcoming programs.

Upcoming Conferences


  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–9am ET    CME/CE Accredited Session


Cardiology and COVID-19: What Do We Need to Know? (June 2021)

Peter Libby, MD


With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues. 

Peter Libby, MD

Cardiovascular Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA

9:10–10:10am ET    CME/CE Accredited Session


Cardiovascular Risk Reduction: Optimizing Patient Identification for Improved Cardioprotective Outcomes

Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC | Pamela Morris, MD, FACC, FAHA, FASPC, FNLA


In this virtual, case-based medical education program held during CardiologyNOW 2021, expert faculty will get to the heart of the matter by discussing how to identify patients who are still at risk for cardiovascular events and may benefit from additional treatment despite management of other risk factors.


Associate Professor of Medicine & Epidemiology, Director of Women’s Cardiovascular Health, Associate Director of Preventive Cardiology, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD

Pamela Morris, MD, FACC, FAHA, FASPC, FNLA

Professor of Medicine, Cardiology, Director, Seinsheimer Cardiovascular Health Program, Co-Director, Women's Heart Care, Medical University of South Carolina, Charleston, SC

Supported by Amarin Pharma Inc.

10:20–11:05am ET    Non-CME Industry Theater


Clinical Considerations in Stroke or Transient Ischemic Attack

Ted Okerson, MD, FACP, FACE


  • Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

Ted Okerson, MD, FACP, FACE

Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.

Sponsored by AstraZeneca Pharmaceuticals, LP

11:15am–12:15pm ET    CME/CE Accredited Session


Pulmonary Arterial Hypertension and Congenital Heart Disease: Advancing Treatment Paradigms, Optimizing Outcomes, and Improving Quality of Life

Ioana R. Preston, MD | Richard Krasuski, MD, FACC, FAHA, FESC


This activity aims to integrate new evidence on the treatment of CHD-PAH into clinical practice, by providing HCPs with a review of CHD-PAH pathophysiology, practical strategies for risk assessment based on underlying CHD and attributes of PAH, and evidence supporting the use of PAH therapies in patients with CHD-PAH.

Ioana R. Preston, MD

Pulmonary Function Lab Director, Director, Pulmonary Hypertension Center, Associate Professor, Tufts University School of Medicine, Boston, Massachusetts

Richard Krasuski, MD, FACC, FAHA, FESC

Professor of Medicine and Pediatrics, Director of the Adult Congenital Heart Disease Center, Director of Hemodynamic Research, Medical Director, CTEPH Program, Director of the Duke University Collaborative Cardiovascular Society (DUCCS), Duke University Medical Center, Durham, North Carolina

Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

12:25–1:25pm ET    CME/CE Accredited Session


Polyvascular Patients: Are You Doing Enough to Reduce Risk of Recurrent Events?

Christian T. Ruff, MD, MPH | Elaine Hylek, MD, MPH


Cardiology expert, Christian Ruff, MD, MPH & primary care specialist, Elaine Hylek, MD, MPH will review the latest research and recommendations for patients with polyvascular disease.  The faculty also will discuss patient cases that cover long-term atherothrombotic risks, chronic coronary artery disease (CAD)/peripheral artery disease (PAD), benefits of direct oral anticoagulants (DOACs), and considerations for the multidisciplinary team.

Christian T. Ruff, MD, MPH

Assistant Professor of Medicine, Harvard Medical School, Investigator, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA

Elaine Hylek, MD, MPH

Professor of Medicine, Boston University School of Medicine, Director, Thrombosis and Anticoagulation Service, Boston Medical Center, Boston, MA

Supported by Janssen Scientific Affairs, LLC

1:30–2pm ET    Non-CME Industry Theater

Cardiovascular Medicine

The Interplay Between Optimizing Heart Failure Management and Delivering Quality Care


The clinical course of heart failure is punctuated by multiple episodes of hospitalization,1-3 leading to poor outcomes and high and escalating costs.4,5 This highlights the need to reimagine how heart failure care is delivered. In this episode, featuring Dr Nihar Desai of the Yale School of Medicine, we will explore the interplay between implementing quality improvement initiatives, specifically value-based care models, and optimizing heart failure care. 

Sponsored by Novartis Pharmaceuticals Corporation